Evidence map›Paper›PMID 38622982›Full record

ArticleAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2024

Increased susceptibility to azithromycin of Pseudomonas aeruginosa biofilms using RPMI 1640 testing media.

Adrian Jimenez San San Mauro, Niels Høiby, Oana Ciofu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Menadione as Antibiotic Adjuvant AgainstAntibiotics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Adrian Jimenez San San MauroInstitute of Immunology & Microbiology, Costerton Biofilm Center, University of Copenhagen, Copenhagen, Denmark.
Niels HøibyInstitute of Immunology & Microbiology, Costerton Biofilm Center, University of Copenhagen, Copenhagen, Denmark.
Oana CiofuInstitute of Immunology & Microbiology, Costerton Biofilm Center, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-5648-4858
University of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azithromycin (AZM) is efficient for treatment of chronic Pseudomonas aeruginosa biofilm lung infections, despite of resistance in conventional susceptibility testing. It has been shown that planktonic P. aeruginosa are more susceptible to AZM when tested in RPMI 1640 medium. The aim of the study was to test the susceptibility to AZM of P. aeruginosa biofilms in LB vs RPMI 1640 media. We investigated the effect of AZM on planktonic and biofilms of (WT) P. aeruginosa (PAO1), the hypermutable (ΔmutS) and the antibiotic-resistant phenotype(ΔnfxB) mutants. The effect of AZM on young and mature biofilms was investigated in the modified Calgary Biofilm Device by estimation of the minimal biofilm inhibitory concentration (MBIC). The AZM MBIC

Indexed as

Anti-Bacterial AgentsAzithromycinBiofilmsMicrobial Sensitivity TestsPseudomonas aeruginosaCulture MediaDrug Resistance, BacterialHumansAnti-Bacterial AgentsAzithromycinCulture MediaazithromycinbiofilmPseudomonas aeruginosaRPMI‐1640

Identifiers

PMID38622982
PMCPMC11582341
OpenAlexW4394853570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.